Poor Mental Health Rising; Eating Disorder Uncertainties; Dementia Life Expectancy

Three U.S. health surveys indicated increasing prevalence of poor mental health from 2011 to 2022. (JAMA Network Open)

The FDA is reviewing whether investigational suzetrigine — billed as a nonaddictive opioid alternative — should be approved for acute pain. (Washington Post)

Ketamine use prevalence increased 82% from 2015 to 2019 and by 40% from 2021 to 2022, according to National Survey on Drug Use and Health data. (Journal of Affective Disorders)

Many clinicians are unsure of what to ask if they suspect their patient has an eating disorder. (STAT)

A meta-analysis showed that the average life expectancy of people with dementia at time of diagnosis ranged from 5.7 years at age 65 to 2.2 years at age 85 in men, and from 8 to 4.5 years, respectively, in women. (The BMJ)

California wildfire survivors are facing increased risks for anxiety, depression, and post-traumatic stress disorder. (ABC News)

A Biden appointee at the VA who advocates treating mental health disorders with psychedelic drugs wants to join forces with Robert F. Kennedy Jr. (Politico)

A low-intensity online intervention flopped for improving distress, depressive, and anxiety symptoms in a randomized trial in Hong Kong, but did help reduce general stress. (JAMA Network Open)

Overdose death rates in the U.S. remain higher — by a substantial margin — than in other countries, according to a report from the Commonwealth Fund.

Johnson & Johnson is set to acquire Intra-Cellular Therapies, developer of the schizophrenia and bipolar depression drug lumateperone (Caplyta), for $14.6 billion. (BioPharma Dive)

Peter Fenwick, MD, a neuropsychiatrist who was an expert on near-death experiences, died last year at age 89. (New York Times)

The American Psychological Association praised the Substance Use and Mental Health Services Administration for boosting the incentives to those battling substance use disorders.

Please enable JavaScript to view the comments powered by Disqus.